Analytical Validation of a Novel MicroRNA Panel for Risk Stratification of Cognitive Impairment
Open Access
- 26 June 2023
- journal article
- research article
- Published by MDPI AG in Diagnostics
- Vol. 13 (13) , 2170
Abstract
We have been developing a novel approach to identify cognitive impairment-related biomarkers by profiling brain-enriched and inflammation-associated microRNA (miRNA) in plasma specimens of cognitively unimpaired and cognitively impaired patients. Here, we present an analytical validation of the novel miRNA panel, CogniMIR®, using two competing quantitative PCR technologies for the expression analysis of 24 target miRNAs. Total RNA from the plasma specimens was isolated using the MagMAX mirVana Kit, and RT-qPCR was performed using stem-loop-based TaqMan and LNA-based qPCR assays. Evaluation of RNA dilution series for our target 24 miRNAs, performed by two operators on two different days, demonstrated that all CogniMIR® panel miRNAs can be reliably and consistently detected by both qPCR technologies, with sample input as low as 20 copies in a qPCR reaction. Intra-run and inter-run repeatability and reproducibility analyses using RNA specimens demonstrated that both operators generated repeatable and consistent Cts, with R2 values of 0.94 to 0.99 and 0.96 to 0.97, respectively. The study results clearly indicate the suitability of miRNA profiling of plasma specimens using either of the qPCR technologies. However, the LNA-based qPCR technology appears to be more operationally friendly and better suited for a CAP/CLIA-certified clinical laboratory.Keywords
Funding Information
- National Institute on Aging (R44AG044860)
This publication has 26 references indexed in Scilit:
- Aging and aging-associated diseases: a microRNA-based endocrine regulation hypothesisAging, 2018
- Circulating brain-enriched microRNAs as novel biomarkers for detection and differentiation of neurodegenerative diseasesAlzheimer's Research & Therapy, 2017
- Universal screening test based on analysis of circulating organ-enriched microRNAs: a novel approach to diagnostic screeningExpert Review of Molecular Diagnostics, 2014
- Plasma microRNA biomarkers for detection of mild cognitive impairment: Biomarker Validation StudyAging, 2013
- P1–226: Early detection of Alzheimer's disease by analysis of brain‐enriched miRNA biomarkers in plasmaAlzheimer's & Dementia, 2013
- Circulating cell-free microRNA as biomarkers for screening, diagnosis and monitoring of neurodegenerative diseases and other neurologic pathologiesFrontiers in Cellular Neuroscience, 2013
- The serum miR‐21 level serves as a predictor for the chemosensitivity of advanced pancreatic cancer, and miR‐21 expression confers chemoresistance by targeting FasLMolecular Oncology, 2012
- Plasma microRNA biomarkers for detection of mild cognitive impairmentAging, 2012
- Circulating MicroRNAs as Minimally Invasive Biomarkers for Cancer Theragnosis and PrognosisFrontiers in Genetics, 2011
- Circulating microRNAs as stable blood-based markers for cancer detectionProceedings of the National Academy of Sciences of the United States of America, 2008